^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Prolymphocytic Leukemia
    Drug:Campath (alemtuzumab) (CD52 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    12/22/2021
    Excerpt:
    T-Cell Prolymphocytic Leukemia...Other recommended regimens...FMC...followed by alemtuzumab...
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    12/22/2021
    Excerpt:
    T-Cell Prolymphocytic Leukemia...Preferred regimens...Alemtuzumab...
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    12/22/2021
    Excerpt:
    T-Cell Prolymphocytic Leukemia...Other recommended regimens...Alemtuzumab + pentostatin in selected patients
    Secondary therapy:
    pentostatin